Desvenlafaxine Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 25 mg, 50 mg, 100 mg
Reference Brands: Pristiq®(US & EU), Khedezla®(US)
Category: Antipsychotropic Drugs
Desvenlafaxine Extended-Release Tablets is available in Extended-Release Tablets and strengths such as 25 mg, 50 mg, 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Desvenlafaxine Extended-Release Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Desvenlafaxine Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: In the United States, desvenlafaxine extended-release tablets are FDA-approved for the treatment of major depressive disorder (MDD) in adults. As an SNRI, it requires a Boxed Warning regarding the risk of suicidal thoughts and behaviors in young individuals. Regulatory compliance includes GMP manufacturing, bioequivalence studies for generics, and ongoing post-marketing surveillance. Labeling must reflect FDA-approved indications, dosing, and adverse effects. In the European Union, desvenlafaxine is not widely marketed, but regulatory pathways exist for national or decentralized approval. Applications must include clinical efficacy, pharmacovigilance plans, and Risk Management Plans (RMPs). For compliant global sourcing, visit Pharmatradz.com. .
Frequently Asked Questions
Related Products
Risperidone Long-Acting Injection
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Form: Long-Acting Injection
Reference Brands: Risperdal Consta(US &EU)
View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)
Strength:
200 mg/mL, 500 mg/mL
Form: Long-acting IM Injection (Depot)
Reference Brands: Clopixol Depot®(US)
View Details
Zuclopenthixol Short-Acting Intramuscular Injection
Strength:
50 mg/mL
Form: Short-acting Intramuscular Injection
Reference Brands: Clopixol-Acuphase®
View Details
Zuclopenthixol Tablets
Strength:
10 mg, 25 mg, 40 mg
Form: Oral Tablets
Reference Brands: Clopixol®(EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
